Aphria (NASDAQ: APHA) is one of 33 public companies in the “Medicinals & botanicals” industry, but how does it compare to its peers? We will compare Aphria to similar companies based on the strength of its profitability, analyst recommendations, valuation, risk, earnings, institutional ownership and dividends.
Risk & Volatility
Aphria has a beta of 2.12, meaning that its share price is 112% more volatile than the S&P 500. Comparatively, Aphria’s peers have a beta of 2.56, meaning that their average share price is 156% more volatile than the S&P 500.
This is a breakdown of current recommendations and price targets for Aphria and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Aphria presently has a consensus target price of $9.88, suggesting a potential upside of 112.37%. As a group, “Medicinals & botanicals” companies have a potential upside of 97.53%. Given Aphria’s stronger consensus rating and higher possible upside, research analysts clearly believe Aphria is more favorable than its peers.
Earnings & Valuation
This table compares Aphria and its peers gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Aphria||$405.96 million||-$63.21 million||-77.50|
|Aphria Competitors||$218.50 million||-$99.79 million||1.73|
Aphria has higher revenue and earnings than its peers. Aphria is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Institutional & Insider Ownership
11.3% of Aphria shares are owned by institutional investors. Comparatively, 21.6% of shares of all “Medicinals & botanicals” companies are owned by institutional investors. 25.8% of shares of all “Medicinals & botanicals” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
This table compares Aphria and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Aphria beats its peers on 8 of the 13 factors compared.
Aphria Company Profile
Aphria Inc. cultivates, processes, produces, markets, distributes, and sells medical cannabis in Canada and internationally. The company offers pharmaceutical-grade medical cannabis, adult-use cannabis, and cannabis-derived extracts and derivative cannabis products under the Solei, RIFF, Good Supply, Aphria, P'tite Pof, and Broken Coast brands. It serves patients and consumers through distributors and online. The company is headquartered in Leamington, Canada.
Receive News & Ratings for Aphria Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aphria and related companies with MarketBeat.com's FREE daily email newsletter.